Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTX Context Therapeutics	$0.63 -3.6%	$0.75	$0.49 ▼ $2.75	$56.46M	1.86	302,288 shs	170,618 shs
HOWL Werewolf Therapeutics	$1.22 -5.4%	$1.02	$0.60 ▼ $4.18	$54.75M	0.66	441,885 shs	303,865 shs
MTVA MetaVia	$0.73 -2.4%	$0.83	$0.63 ▼ $5.30	$14.32M	0.18	406,276 shs	651,867 shs
TELO Telomir Pharmaceuticals	$1.96 -2.0%	$2.39	$1.85 ▼ $8.40	$59.53M	-0.38	152,219 shs	322,674 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTX Context Therapeutics	-3.56%	-5.23%	-20.33%	-10.85%	-68.53%
HOWL Werewolf Therapeutics	-5.43%	-14.08%	+23.23%	+1.67%	-60.26%
MTVA MetaVia	-2.39%	+5.76%	+9.76%	-50.53%	+73,209,900.00%
TELO Telomir Pharmaceuticals	-2.00%	-8.84%	-26.32%	-57.21%	-64.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNTX Context Therapeutics	3.0668 of 5 stars	3.6	2.0	3.5	1.7	1.3
HOWL Werewolf Therapeutics	3.7043 of 5 stars	3.5	3.0	3.3	5.0	0.6
MTVA MetaVia	2.4212 of 5 stars	3.5	0.0	3.3	0.0	1.3
TELO Telomir Pharmaceuticals	2.2497 of 5 stars	3.8	0.0	3.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTX Context Therapeutics	3.20	Buy	$6.00	853.29% Upside
HOWL Werewolf Therapeutics	3.00	Buy	$8.33	583.06% Upside
MTVA MetaVia	3.00	Buy	$7.50	924.45% Upside
TELO Telomir Pharmaceuticals	3.50	Strong Buy	$15.00	665.31% Upside

Current Analyst Ratings Breakdown

Latest MTVA, HOWL, TELO, and CNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	MTVA MetaVia	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $3.00
5/9/2025	HOWL Werewolf Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $6.00
5/8/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/29/2025	CNTX Context Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/29/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/21/2025	CNTX Context Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/16/2025	MTVA MetaVia	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
4/9/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
3/21/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
3/21/2025	CNTX Context Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/21/2025	MTVA MetaVia	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$0.74 per share	N/A
HOWL Werewolf Therapeutics	$1.14M	47.90	N/A	N/A	$3.08 per share	0.40
MTVA MetaVia	N/A	N/A	N/A	N/A	$3.44 per share	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.02 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTX Context Therapeutics	-$23.96M	-$0.31	N/A	N/A	N/A	N/A	-58.76%	-55.80%	8/6/2025 (Estimated)
HOWL Werewolf Therapeutics	-$37.37M	-$1.67	N/A	N/A	N/A	-578.80%	-58.83%	-38.45%	8/14/2025 (Estimated)
MTVA MetaVia	-$12.47M	N/A	0.00	N/A	N/A	N/A	-189.12%	-122.31%	8/13/2025 (Estimated)
TELO Telomir Pharmaceuticals	-$16.53M	-$0.42	N/A	N/A	N/A	N/A	-1,170.58%	-832.67%	8/12/2025 (Estimated)

Latest MTVA, HOWL, TELO, and CNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	CNTX Context Therapeutics	-$0.05	-$0.05	N/A	-$0.05	N/A	N/A
5/14/2025	Q1 2025	MTVA MetaVia	-$0.57	-$0.36	+$0.21	-$0.36	N/A	N/A
5/12/2025	Q1 2025	TELO Telomir Pharmaceuticals	-$0.10	-$0.07	+$0.03	-$0.07	N/A	N/A
5/8/2025	Q1 2025	HOWL Werewolf Therapeutics	-$0.44	-$0.40	+$0.04	-$0.40	$0.30 million	N/A
3/20/2025	Q4 2024	CNTX Context Therapeutics	-$0.05	-$0.04	+$0.01	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A
MTVA MetaVia	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTX Context Therapeutics	N/A	36.91	36.91
HOWL Werewolf Therapeutics	0.29	10.10	10.10
MTVA MetaVia	N/A	2.41	2.41
TELO Telomir Pharmaceuticals	N/A	1.94	1.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTX Context Therapeutics	14.03%
HOWL Werewolf Therapeutics	64.84%
MTVA MetaVia	1.37%
TELO Telomir Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CNTX Context Therapeutics	2.80%
HOWL Werewolf Therapeutics	23.60%
MTVA MetaVia	1.05%
TELO Telomir Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTX Context Therapeutics	7	89.70 million	72.72 million	Not Optionable
HOWL Werewolf Therapeutics	40	44.87 million	35.16 million	Optionable
MTVA MetaVia	8	19.56 million	8.53 million	N/A
TELO Telomir Pharmaceuticals	1	29.76 million	N/A	N/A

MTVA, HOWL, TELO, and CNTX Headlines

Recent News About These Companies

Telomir Pharma’s Telomir-1 shows dose-dependent restoration of neurological, liver & kidney functions in preclinical for Wilson’s disease

June 14 at 11:03 AM | pharmabiz.com

TELO Rises on Promising Telomir-1 Preclinical Results

June 13 at 3:50 PM | insidermonkey.com

TELO Rises on Promising Telomir-1 Preclinical Results

June 13 at 3:34 PM | msn.com

TELO Continues Trend of Significant Trial Announcements

June 11 at 5:23 PM | msn.com

Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model

June 11 at 9:30 AM | accessnewswire.com

Telomir Pharmaceuticals Announces Telomir-1 Resets the Body’s Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated ...

June 7, 2025 | usatoday.com

TELO Data Indicates Aging Reversal Potential

June 6, 2025 | finance.yahoo.com

Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome

June 5, 2025 | accessnewswire.com

Telomir announces positive preclinical data for its novel oral AMD therapeutic

June 3, 2025 | ophthalmologytimes.com

Telomir Pharmaceuticals Joins BIO Convention for Partnerships

June 2, 2025 | tipranks.com

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform

June 2, 2025 | accessnewswire.com

Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration Animal Model Using FDA ...

May 29, 2025 | finanznachrichten.de

TELO Produces Results with Exciting AMD Implications

May 29, 2025 | msn.com

Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints

May 29, 2025 | accessnewswire.com

Telomir Pharmaceuticals CFO Michelle Yanez Leaves Company; Resignation Was a Mutual Separation

May 21, 2025 | marketwatch.com

Telomir Pharmaceuticals Appoints New Chief Financial Officer

May 21, 2025 | tipranks.com

Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND

May 21, 2025 | accessnewswire.com

Telomir Pharmaceuticals

May 19, 2025 | thepharmaletter.com

Telomir unveils new drug candidate against resistant bacteria

May 16, 2025 | investing.com

Telomir Pharma touts breakthrough in drug-resistant infections

May 16, 2025 | thepharmaletter.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTVA, HOWL, TELO, and CNTX Company Descriptions

Context Therapeutics NASDAQ:CNTX

$0.63 -0.02 (-3.56%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.62 -0.01 (-1.81%)

As of 06/13/2025 07:41 PM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Werewolf Therapeutics NASDAQ:HOWL

$1.22 -0.07 (-5.43%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.25 +0.03 (+2.87%)

As of 06/13/2025 06:34 PM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

MetaVia NASDAQ:MTVA

$0.73 -0.02 (-2.39%)

As of 06/13/2025 03:58 PM Eastern

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

Telomir Pharmaceuticals NASDAQ:TELO

$1.96 -0.04 (-2.00%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.96 0.00 (-0.20%)

As of 06/13/2025 06:54 PM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time